Company Overview and News
KUALA LUMPUR (Sept 12): Datuk Tony Tiah Thee Kian, who launched a mandatory takeover offer (MGO) for TA Enterprise Bhd at 66 sen per share in July, has failed to garner the required acceptance from minority shareholders which would have given him control of over 50% of the total voting shares in the group.
4898 5158 BSMAF 1818
Pesona Metro Holdings Bhd (Sept 5, 35 sen) Maintain hold with a higher target price (TP) of 32 sen: Pesona Metro Holdings Bhd announced that it had been awarded a new contract from TA Global Bhd worth RM264.3 million for the construction of serviced apartment in Bandar Sri Damansara, Petaling Jaya.
KUALA LUMPUR: JF Apex expects IJM Corp Bhd , Pesona Metro Holdings Bhd , Borneo Aqua Harvest Bhd and Sapura Energy Bhd to be among the stocks to watch on Wednesday.
5158 8311 0098
KUALA LUMPUR (Sept 4): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Sept 5) may include the following: IJM Corp Bhd, Pesona Metro Holdings Bhd, Borneo Aqua Harvest Bhd, Ark Resources Bhd, Sapura Energy Bhd and UEM Edgenta Bhd
7007 1368 5158 8311 0098
KUALA LUMPUR (July 5): The FBM KLCI is seen trending sideways today ahead of the Friday deadline for U.S. trade tariffs on China, that has kept global investors on tenterhooks.
KUALA LUMPUR (July 4): Based on the corporate announcements and news flow today, companies in focus on Thursday (July 5) may include: Serba Dinamik, Xian Leng, SCGM, Perdana Petroleum, TA Global, MNRB, China Automobile Parts and JMR.
4898 7108 6459 5229 7043 5158 BSMAF 7121 1818
KUALA LUMPUR (July 4): Shareholders of TA Global Bhd stand to receive a mandatory general offer (MGO) from Datuk Tony Tiah Thee Kian if his interest in TA Enterprise Bhd crosses the 50% mark.
4898 5158 BSMAF 1818
THE ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723
KUALA LUMPUR: Datuk Tony Tiah Thee Kian has launched a mandatory takeover offer (MGO) for TA Enterprise Bhd at 66 sen per share after acquiring 14.33 million shares or a 0.84% stake in the stockbroking firm for prices between 61 sen and 66 sen from the open market.
4898 5158 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...